4.7 Review

Hypercontractile Esophagus From Pathophysiology to Management: Proceedings of the Pisa Symposium

期刊

AMERICAN JOURNAL OF GASTROENTEROLOGY
卷 116, 期 2, 页码 263-273

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.14309/ajg.0000000000001061

关键词

-

向作者/读者索取更多资源

Hypercontractile esophagus (HE) is a heterogeneous motility disorder characterized by high-contractile peristaltic sequences on esophageal high-resolution manometry (HRM). The pathophysiology may involve excessive cholinergic drive and asynchronous muscle contractions. Empiric trial of proton pump inhibitor is recommended as first-line therapy, followed by consideration of other medications and endoscopic intervention.
Hypercontractile esophagus (HE) is a heterogeneous major motility disorder diagnosed when >= 20% hypercontractile peristaltic sequences (distal contractile integral >8,000 mm Hg*s*cm) are present within the context of normal lower esophageal sphincter (LES) relaxation (integrated relaxation pressure < upper limit of normal) on esophageal high-resolution manometry (HRM). HE can manifest with dysphagia and chest pain, with unclear mechanisms of symptom generation. The pathophysiology of HE may entail an excessive cholinergic drive with temporal asynchrony of circular and longitudinal muscle contractions; provocative testing during HRM has also demonstrated abnormal inhibition. Hypercontractility can be limited to the esophageal body or can include the LES; rarely, the process is limited to the LES. Hypercontractility can sometimes be associated with esophagogastric junction (EGJ) outflow obstruction and increased muscle thickness. Provocative tests during HRM can increase detection of HE, reproduce symptoms, and predict delayed esophageal emptying. Regarding therapy, an empiric trial of a proton pump inhibitor, should be first considered, given the overlap with gastroesophageal reflux disease. Calcium channel blockers, nitrates, and phosphodiesterase inhibitors have been used to reduce contraction vigor but with suboptimal symptomatic response. Endoscopic treatment with botulinum toxin injection or pneumatic dilation is associated with variable response. Per-oral endoscopic myotomy may be superior to laparoscopic Heller myotomy in relieving dysphagia, but available data are scant. The presence of EGJ outflow obstruction in HE discriminates a subset of patients who may benefit from endoscopic treatment targeting the EGJ.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据